Agenus shared JAMA’s post on LinkedIn, adding:
“Colorectal cancer is moving in the wrong direction.
A new article from JAMA reports that colorectal cancer (CRC) is now the leading cause of cancer-related death in people under 50—years earlier than originally projected.
At Agenus, this urgency is exactly why we are advancing botensilimab + balstilimab (BOT+BAL)—an investigational immunotherapy combination which helps the immune system recognize and respond to CRC tumors that have historically been resistant to treatment.
Our research in CRC spans multiple disease settings, including early-stage disease as well as advanced, treatment-refractory disease, reflecting a long-term commitment to expanding where immunotherapy can make a difference.
We believe innovation in CRC must do more than extend survival—it must help patients preserve quality of life and reduce reliance on treatments that can carry long-term physical consequences, such as chemotherapy, radiation, and radical surgery—especially for younger patients facing this disease.
This is the promise driving our work.
Learn more about our CRC research and immunotherapy approach.”
Quoting JAMA’s post:
“Analysis of US mortality data from 1990 to 2023 indicates breast cancer, lung cancer, and leukemia deaths decreased in people younger than 50, while Colorectal Cancer mortality increased, rising from fifth to first among cancer deaths in this age group.
The majority of cases present at an advanced stage, highlighting the need for increased symptom awareness and earlier screening. National trends suggest ongoing prevention and early detection strategies are vital for addressing early-onset colorectal cancer.”
Title: Leading Cancer Deaths in People Younger Than 50 Years
Authors: Rebecca L. Siegel, Nikita Sandeep Wagle, Ahmedin Jemal
Read the Full Article on JAMA Network
More posts about Agenus.
